Paradigm Biopharmaceuticals Ltd.ASX: PAR

Paradigm Doses First UK Participant in Phase 3 Trial

Oct 26, 2022 at 2:55 AM UTC · Issued by Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd has released a press release.

View Attachment